Subcut / IV
Ustekinumab
Stelara
- Mechanism of Action
- A human monoclonal antibody directed against p40, a shared subunit present in both IL-12 and IL-23. Inhibition of IL-12 results in reduced differentiation of TH1 cells, while inhibition of IL-23 results in reduced induction of TH17 cells.
Clinical Use
- Indications
- Severe refractory Crohn’s disease
- Refractory psoriatic arthritis
- Moderate to severe plaque psoriasis
- Adverse Effects
- Injection site reactions
- Upper respiratory tract infection
- Dizziness
- Headache
- Nausea / vomiting / diarrhoea
- Myalgias / arthralgias
- Fatigue
Want more info like this?
- Your electronic clinical medicine handbook
- Guides to help pass your exams
- Tools every medical student needs
- Quick diagrams to have the answers, fast
- Quizzes to test your knowledge
Explore